



# PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Ref: PDL: MAY: 2016

Dated: 28.05.2016

The Bombay Stock Exchange Limited,  
Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai,  
Maharashtra

**SUBJECT : SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE  
QUARTER ENDED ON 31<sup>ST</sup> MARCH, 2016**


Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Audited Financial Results of the Company for the quarter ended on 31<sup>st</sup> March, 2016 as approved by the Board of Directors in its meeting held on Saturday, the 28<sup>th</sup> day of May, 2016, along with the Report of the Auditors.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

Thanking You

For Parabolic Drugs Limited

  
Authorised Signatory

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B,  
Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,  
District Panchkula (Hry.) India Tel. : +91-1733-256380

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India  
Tel. : +91-1762-308657

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India  
Tel. : +91-172-2591443

Works - III : Village Chachrauli, Tehsil Derabassi, Lalru, Distt. Mohali (Pb.)  
Tel. : +91-1762-308792

# **S. K. BANSAL & CO.**

**CHARTERED ACCOUNTANTS**

Kothi No. : 3193, Sector 28-D,

Chandigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.bansals.in

Phones : Off. : 2657202

2651578

2657644


Fax : 2652428

## **Auditor's Report on the Standalone Financial Results of Parabolic Drugs Limited pursuant to the Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015**

### **Independent Auditors' Report to the Board of Directors of Parabolic Drugs Limited**

We have audited the accompanying Statement of Standalone Financial Results of **Parabolic Drugs Limited** ("the company") for the quarter and year ended 31<sup>st</sup> March, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. Attention is drawn to the fact that the results regarding the amounts for the quarter ended 31<sup>st</sup> March, 2016 as reported in these standalone financial statements are the balancing amounts between audited amounts in respect of full financial year and the published year to date amounts upto the end of the third quarter of the financial year. Also, the amounts upto the end of the third quarter had only been reviewed and not subjected to audit. These standalone financial results have been prepared on the basis of standalone financial statements and reviewed quarterly financial results up to the end of the third quarter, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these standalone financial results based on our review of the annual financial results for the nine months ended 31<sup>st</sup> December,2015 which are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard(AS) 25, Interim Financial reporting, issued pursuant to the Companies (Accounting Standards ) Rules,2006 read with Rule 7 of the Companies (Accounts) Rules,2014 in respect of section 133 of the Companies Act,2013 and other accounting principles generally accepted in India; and our audit of standalone financial statements as at and for the year ended 31<sup>st</sup> March,2016.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement(s). An audit includes examining , on a test basis, evidence supporting the amounts disclosed as standalone financial results. An audit also includes assessing the accounting



principles used and significant estimates by the management. We believe that our audit provides a reasonable basis of our opinion.


**Opinion**


In our opinion and to the best of our information and subject to Annexure –A, and according to the explanations given to us, the standalone financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 in this regard; and
- (ii) gives a true and fair view of the net Loss and other financial information for the year ended 31<sup>st</sup> March, 2016.

Chandigarh;  
Dated:28<sup>th</sup> May 2016

FOR S.K. BANSAL & CO.,  
CHARTERED ACCOUNTANTS



  
(S.K. Bansal)  
Partner

Membership No: 013147

Name: M/s. S.K. Bansal & Co.  
Chartered Accountants  
[FRN No.002222N]

Address: Kothi No. 3193, Sector 28 – D,  
Chandigarh-160002


**Annexure A**

**Notes to the standalone financial results of M/s Parabolic Drugs Limited for the Quarter /year ended 31<sup>st</sup> March 2016**

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Figures of the previous year/Quarter/twelve month's period have been rearranged/regrouped wherever considered necessary.

Chandigarh;  
Dated: 28<sup>th</sup> May 2016

FOR S.K. BANSAL & CO.,  
CHARTERED ACCOUNTANTS  
[FRN No.002222N]



  
(S.K.Bansal)

Membership No: 013147

# **S. K. BANSAL & CO.**

**CHARTERED ACCOUNTANTS**

Kothi No. : 3193, Sector 28-D,  
Chandigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.bansals.in

Phones : Off. : 2657202

2651578

2657644

Fax : 2652428

## **Auditor's Report on the Consolidated Financial Results of Parabolic Drugs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### **Independent Auditors' Report to the Board of Directors of Parabolic Drugs Limited**


We have audited Consolidated Financial Results of **Parabolic Drugs Limited** ("the company") and its subsidiaries (the company and its subsidiaries together referred to as "the group") for the quarter and year ended 31<sup>st</sup> March, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015. These consolidated financial results , which are the responsibility of the Company's management has been prepared in accordance with recognition and measurement principles laid down in Accounting Standard(AS) 25, Interim Financial reporting, issued pursuant to the Companies (Accounting Standards ) Rules,2006 read with Rule 7 of the Companies (Accounts) Rules,2014 in respect of section 133 of the Companies Act,2013 and other accounting principles generally accepted in India. Our responsibility is to express an opinion on these consolidated financial results based on our audit.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement(s) . An audit includes examining, on a test basis, evidence supporting the amounts disclosed as standalone financial results. An audit also includes assessing the accounting principles used and significant estimates by the management. We believe that our audit provides a reasonable basis of our opinion.

#### ***Opinion***

In our opinion and to the best of our information and subject to Annexure –A, and according to the explanations given to us, the consolidated financial results:

- (i) includes the annual financial results for the year ended 31<sup>st</sup> March,2016 of the following entities to the annual financial results ;
  - a) Parabolic Research Labs Limited
  - b) Ziven Lifesciences Limited




**S. K. BANSAL & CO.**  
**CHARTERED ACCOUNTANTS**  
CHANDIGARH

- (ii) has been presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 in this regard; and
- (iii) gives a true and fair view of the consolidated Net Loss and other financial information for the year ended 31<sup>st</sup> March, 2016.

Chandigarh;  
Dated: 28th May 2016

**FOR S.K. BANSAL & CO.,**  
**CHARTERED ACCOUNTANTS**



  
**(S.K. Bansal)**  
**Partner**

**Membership No: 013147**

**Name: M/s. S.K. Bansal & Co.**  
**Chartered Accountants**

**[FRN No.002222N]**

**Address: Kothi No. 3193, Sector 28 – D,**  
**Chandigarh-160002**


**Annexure A**


**Notes to the Consolidated financial results of M/s Parabolic Drugs Limited for the Quarter /year ended 31<sup>st</sup> March 2016**

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Figures of the previous year/Quarter/twelve month's period have been rearranged/regrouped wherever considered necessary.

Chandigarh;  
Dated: 28<sup>th</sup> May 2016

FOR S.K. BANSAL & CO.,  
CHARTERED ACCOUNTANTS  
[FRN No.002222N]



  
(S.K. Bansal)  
Membership No: 013147.



# PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



**Parabolic Drugs Limited**  
Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh  
Statement of Audited Financial Results for the Quarter/Year Ended 31st March, 2016

Particulars	Three months ended 31/03/2016	Preceding Three months ended 31/12/2015	Corresponding Three months ended 31/03/2015 in the previous year	Year to date figures for Current Year ended 31/03/2016	Previous Year ended 31/03/2015	Year to date figures for Current Year ended 31/03/2016	Previous Year ended 31/03/2015
	Audited Stand-alone	Unaudited Stand-alone	Audited Stand-alone	Audited Stand-alone	Audited Stand-alone	Audited Consolidated	Audited Consolidated
<b>1 Income from Operations</b>							
Gross Sales	14.74	22.50	27.82	83.10	239.93	84.34	240.30
Less : Excise Duty	(1.51)	(2.37)	(1.21)	(8.88)	(11.15)	(8.88)	(11.15)
(a) Net Sales/Income from Operations (Net of excise duty)	13.23	20.13	26.61	74.22	228.78	75.46	229.15
(b) Other Operating Income	0.34	0.41	1.70	1.68	4.24	1.70	4.24
<b>Total Income from Operations (net)</b>	<b>13.57</b>	<b>20.54</b>	<b>28.31</b>	<b>75.90</b>	<b>233.02</b>	<b>77.16</b>	<b>233.39</b>
<b>2 Expenses</b>							
(a) Cost of Materials Consumed	14.78	13.26	41.52	58.20	208.94	59.07	209.32
(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	51.67	132.33	44.86	270.31	46.90	270.60	46.84
(c) Employee Benefits Expense	2.24	2.79	3.73	10.68	17.01	10.91	17.46
(d) Depreciation & Amortisation Expense	15.81	17.09	21.29	67.06	72.97	67.22	73.22
(e) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	24.15	6.67	9.24	42.79	37.51	43.00	37.71
<b>Total Expenses</b>	<b>108.65</b>	<b>172.14</b>	<b>120.64</b>	<b>449.04</b>	<b>383.33</b>	<b>450.80</b>	<b>384.55</b>
Profit/(Loss) from Operations before Other Income, Finance Costs & Exceptional Items (1 - 2)	(95.08)	(151.60)	(92.33)	(373.14)	(150.31)	(373.64)	(151.16)
<b>3 Other Income</b>							
Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(95.08)	(151.60)	(92.33)	(373.14)	(150.31)	(373.64)	(151.16)
<b>5 Finance Costs</b>	28.33	27.04	42.89	107.62	98.69	107.63	98.99
Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(123.41)	(178.64)	(135.22)	(480.76)	(249.00)	(481.27)	(250.15)
<b>8 Exceptional Items</b>							
Profit/(Loss) from Ordinary Activities before tax (7 + 8)	(123.41)	(178.64)	(135.22)	(480.76)	(249.00)	(481.27)	(250.15)
<b>10 Tax expense</b>	4.43	-	153.37	4.43	130.32	4.43	130.32
Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(127.84)	(178.64)	(288.59)	(485.19)	(379.32)	(485.70)	(380.47)
<b>12 Extra Ordinary Items (net of tax expense)</b>							
Net Profit / (Loss) for the period (11-12)	(127.84)	(178.64)	(288.59)	(485.19)	(379.32)	(485.70)	(380.47)
<b>14 Share of Profit/(Loss) of Associates</b>							
<b>15 Minority Interest</b>							
<b>16 Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of Associates (13 + 14 + 15)</b>	<b>(127.84)</b>	<b>(178.64)</b>	<b>(288.59)</b>	<b>(485.19)</b>	<b>(379.32)</b>	<b>(485.70)</b>	<b>(380.47)</b>
<b>17 Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)</b>	61.89	61.89	61.89	61.89	61.89	61.89	61.89
<b>18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	(283.96)	95.03	(291.90)	88.36
<b>19(i) Earnings Per Share (EPS) (before extraordinary items) -Shares of Rs. 10/- each (not annualised)</b>							
(a) Basic	(20.66)	(28.86)	(46.63)	(78.40)	(61.29)	(78.48)	(61.47)
(b) Diluted	(20.66)	(28.86)	(46.63)	(78.40)	(61.29)	(78.48)	(61.47)
<b>19(ii) Earnings Per Share (EPS) (after extraordinary items) -Shares of Rs. 10/- each (not annualised)</b>							
(a) Basic	(20.66)	(28.86)	(46.63)	(78.40)	(61.29)	(78.48)	(61.48)
(b) Diluted	(20.66)	(28.86)	(46.63)	(78.40)	(61.29)	(78.48)	(61.48)
<b>A. PARTICULARS OF SHAREHOLDING</b>							
<b>1 Public Shareholding :</b>							
- Number of Shares	37974587	37,974,587	37974587	37974587	37974587	-	-
- Percentage of Shareholding	61.36	61.36	61.36	61.36	61.36	-	-
<b>2 Promoters and Promoter Group Shareholding :</b>							
(a) Pledged/Encumbered							
- Number of shares	22619927	22,619,927	22619927	22619927	22,619,927.00	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.58	94.58	94.58	94.58	94.58	-	-
- Percentage of shares (as a % of the total share capital of the company)	36.55	36.55	36.55	36.55	36.55	-	-

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B, Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

R & D Centre : 280-281, HSIIDC, Tehsil Barwala, District Panchkula (Hry.) India Tel. : +91-1733-256380

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India Tel. : +91-1762-308657

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India Tel. : +91-172-2591443

Works - III : Village Chachrauli, Tehsil Derabassi, Lalru, Distt. Mohali (Pb.) Tel. : +91-1762-308792

CIN No. : L24231CH1996PLC017755.

website : www.parabolicdrugs.com





# PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



(b) Non-Encumbered							
- Number of shares	1,297,500	1,297,500	1,297,500	1,297,500	1,297,500	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.42	5.42	5.42	5.42	5.42	-	-
- Percentage of shares (as a % of the total share capital of the company)	2.10	2.10	2.10	2.10	2.10	-	-
<b>B. INVESTOR COMPLAINTS</b>				<b>Quarter ended 31/03/2016</b>	<b>Quarter ended 31/03/2015</b>		
Pending at the beginning of the quarter				Nil	Nil		
Received during the quarter				Nil	Nil		
Disposed of during the quarter				Nil	Nil		
Remaining unresolved at the end of the quarter				Nil	Nil		

STATEMENT OF ASSETS & LIABILITIES	Rs in Crores			
	As at 31/03/2016 Audited	As at 31/03/2015 Audited	As at 31/03/2016 Audited	As at 31/03/2015 Audited
	Standalone		Consolidated	
<b>SOURCES OF FUNDS :</b>				
<b>(1) Shareholders' Funds</b>				
(a) Share Capital	61.89	61.89	61.89	61.89
(b) Reserves and Surplus	(769.15)	(283.96)	(777.60)	(291.90)
<b>(2) Share Application Money Pending Allotment</b>	26.00	26.00	26.00	26.00
<b>(3) Minority Interest</b>				
<b>(4) Non-Current Liabilities</b>				
(a) Long-term borrowings	731.53	563.29	729.76	561.37
(b) Deferred tax liabilities (Net)	29.89	25.46	28.97	24.54
(c) Long term provisions	1.51	2.46	1.51	2.46
<b>(5) Current Liabilities</b>				
(a) Short-term borrowings	240.21	394.20	241.63	395.92
(b) Trade payables	93.18	101.91	93.24	102.11
(c) Other current liabilities	161.94	58.89	163.44	60.52
(d) Short-term provisions				
<b>TOTAL</b>	<b>577.00</b>	<b>950.14</b>	<b>568.84</b>	<b>942.91</b>
<b>II ASSETS</b>				
<b>(1) Non-current assets</b>				
(a) Fixed assets				
(i) Tangible assets	371.19	395.05	371.19	395.06
(ii) Intangible assets	0.00	0.08	0.01	0.09
(iii) Capital work-in-progress	6.52	6.52	6.52	6.52
(b) Non-current investments	6.32	6.32	0.13	0.12
(c) Other non-current assets	46.77	91.28	46.92	91.59
<b>(2) Current assets</b>				
(a) Inventories	40.10	315.38	40.36	315.93
(b) Trade receivables	70.06	98.05	70.23	98.24
(c) Cash and cash equivalents	0.64	3.02	0.73	3.20
(d) Short-term loans and advances	31.10	29.70	28.46	27.43
(e) Other current assets	4.30	4.74	4.29	4.73
<b>TOTAL</b>	<b>577.00</b>	<b>950.14</b>	<b>568.84</b>	<b>942.91</b>

#### Notes :

- The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up-to the third quarter of the current financial year.
- During the period under review, the company has incurred loss. Owing to the tightened market conditions and economic stress, the company has witnessed an erosion in the margins of key products.
- There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
- The above financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 28th May 2016 and the same have been audited by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
- Figures of the previous year / period have been rearranged/regrouped wherever considered necessary.
- During the Financial Year 2015-16 most of banks have not charged interest due to NPA classification. The company has made provision of interest amounting to Rs 10352 lacs @ 10.50% Per annum for the year in respect of such loan accounts.
- During the year M/s J.M. Financial Asset Reconstruction Company Private Limited has taken over the loans/debts outstanding of the company from State Bank of Patiala, State Bank of Hyderabad, ICICI Bank Ltd & Uco Bank and provision for interest in respect of these banks has been provided @ 10.50% for the year.
- The company has incurred losses of Rs 48519 Lacs (PY Rs 37932 Lacs) during the current year and the company has net current liabilities of Rs 34913 Lacs (PY Rs 10411 lacs ) as on 31.03.2016. Further the company's accumulated losses have resulted in erosion of its entire net worth. The continuous losses have adversely affected the cash flows of the company.
- The company CDR package stands implemented with cut off date being 30th September 2012 and the company exit from the same w.e.f 28th October 2015.
- During the year the Company has filed the application with Board for Industrial and Financial Reconstruction (BIFR) on 22nd May 2015 and registered on 30th June 2015 vide case no. 82/2015.
- Tax expense include Income Tax & Deferred Tax Liability (Net).

Place : Chandigarh  
Date : 28th May 2016

Pranav Gupta  
Managing Director

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B, Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

R & D Centre : 280-281, HSIIDC, Tehsil Barwala, District Panchkula (Hry.) India Tel. : +91-1733-256380

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India Tel. : +91-1762-308657

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India Tel. : +91-172-2591443

Works - III : Village Chachrauli, Tehsil Derabassi, Lalru, Distt. Mohali (Pb.) Tel. : +91-1762-308792

CIN No. : L24231CH1996PLC017755.

website : www.parabolicdrugs.com